PMID- 36197602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221009
IS  - 2730-6011 (Electronic)
IS  - 2730-6011 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Oct 5
TI  - Rho-associated kinase1 promotes laryngeal squamous cell carcinoma tumorigenesis 
      and progression via the FAK signaling pathway.
PG  - 100
LID - 10.1007/s12672-022-00561-7 [doi]
LID - 100
AB  - Laryngeal squamous cell carcinoma (LSCC) is one of the most common head and neck 
      squamous cell carcinomas (HNSCC). Rho-associated kinase1 (ROCK1) is considered to 
      promote progression of numerous cancers, however, its role in LSCC is still 
      unknown. Here, the expression level of ROCK1 is higher in LSCC tissues than 
      non-tumor tissues, and the expression level of ROCK1 is positively correlated 
      with advanced stage and poor survival prognosis. ROCK1 knockdown in TU686 and 
      TU212 cells dramatically inhibits cellular proliferation, migration and invasion. 
      Whereas the overexpression of ROCK1 reversed these changes. FAK signaling pathway 
      plays an essential role in promoting LSCC progression. Inhibiting FAK activity 
      with TAE226 observably impairs the tumor-promoting effects. In conclusion, ROCK1 
      promotes LSCC tumorigenesis and progression via the FAK signaling pathway, 
      targeting the ROCK1 molecule may represent potential targets for clinical LSCC 
      treatment.
CI  - (c) 2022. The Author(s).
FAU - Yang, Liyun
AU  - Yang L
AD  - Department of Otolaryngology, Gongli Hospital, The Second Military Medical 
      University, Shanghai, 200135, China.
FAU - Qiao, Peipei
AU  - Qiao P
AD  - Department of Otolaryngology, Gongli Hospital, The Second Military Medical 
      University, Shanghai, 200135, China.
FAU - Zhang, Jianwei
AU  - Zhang J
AD  - Department of Otolaryngology, Gongli Hospital, The Second Military Medical 
      University, Shanghai, 200135, China.
FAU - Huang, Shuixian
AU  - Huang S
AD  - Department of Otolaryngology, Gongli Hospital, The Second Military Medical 
      University, Shanghai, 200135, China. enthsx@163.com.
FAU - Hu, An
AU  - Hu A
AD  - Department of Otolaryngology, Gongli Hospital, The Second Military Medical 
      University, Shanghai, 200135, China. juanitohuan@163.com.
LA  - eng
PT  - Journal Article
DEP - 20221005
PL  - United States
TA  - Discov Oncol
JT  - Discover oncology
JID - 101775142
PMC - PMC9535064
OTO - NOTNLM
OT  - FAK
OT  - LSCC
OT  - ROCK1
OT  - Tumorigenesis and progression
COIS- The authors declare that they have no financial disclosure and competing 
      interests.
EDAT- 2022/10/06 06:00
MHDA- 2022/10/06 06:01
PMCR- 2022/10/05
CRDT- 2022/10/05 11:28
PHST- 2022/06/17 00:00 [received]
PHST- 2022/08/08 00:00 [accepted]
PHST- 2022/10/05 11:28 [entrez]
PHST- 2022/10/06 06:00 [pubmed]
PHST- 2022/10/06 06:01 [medline]
PHST- 2022/10/05 00:00 [pmc-release]
AID - 10.1007/s12672-022-00561-7 [pii]
AID - 561 [pii]
AID - 10.1007/s12672-022-00561-7 [doi]
PST - epublish
SO  - Discov Oncol. 2022 Oct 5;13(1):100. doi: 10.1007/s12672-022-00561-7.